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ABSTRACT
Background Treatment of cancer with chemotherapy decreases endurance capacity and muscle
strength. Training during chemotherapy might prevent this. There are no clear guidelines
concerning which type of training and which training dose are effective. This review aims to gain
insight into the different training modalities during chemotherapy and the effects of such training
to improve endurance capacity and muscle strength in order to obtain the knowledge to compose
a future training program which trains cancer patients in the most effective way. Material and
methods A systematic search of PubMed was carried out. In total, 809 studies of randomized
controlled trials studying the effects of training during chemotherapy on endurance capacity and
muscle strength were considered. Only 14 studies met all the inclusion criteria. The studies were
assessed on methodological quality by using Cochrane criteria for randomized controlled trials.
Results The quality of the studies was generally poor and the study populations varied
considerably as the training programs were very heterogeneous. Variables of endurance capacity
reported beneficial effects in 10 groups (59%). Increases due to training ranged from 8% to 31%.
Endurance capacity decreased in nine of 13 control groups (69%), which ranged from 1% to 32%.
Muscle strength improved significantly in 17 of 18 intervention groups (94%), ranging from 2% to
38%. Muscle strength also improved in 11 of 14 control groups (79%), but this increase was only
minimal, ranging from 1.3% to 6.5%. Conclusions This review indicates that training during
chemotherapy may help in preventing the decrease in muscle strength and endurance capacity. It
is important to know which training intensity and duration is the most effective in training cancer
patients, to provide a training program suitable for every cancer patient. Training should be based
on good research and should be implemented into international guidelines and daily practice.
More research is needed.
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Ferlay et al. estimated 3.45 million new cases and 1.75 million
deaths from cancer in Europe in 2012. In combination, cancers
of the female breast, colorectal, prostate and lung represent
almost half of the overall burden of cancer in Europe [1]. The
survival rates have increased during recent years – nowadays
61% of the cancer patients will survive [2]. All these numbers
show a future increase of the number of cancer survivors who
have to deal with the side effects of cancer therapy.
A considerable number of cancer patients receive che-
motherapy or radiotherapy. Side effects include both physical
as well as psychological complications and have a huge impact
on daily life. A frequently reported side effect from chemother-
apy and radiation is cancer-related fatigue [3,4]. One study
found that up to 82% of breast cancer patients experienced
fatigue after their first chemotherapy cycle [5]. Cancer-related
fatigue has a negative effect on muscle strength, endurance
capacity, quality of life and return to work [6–9].
Chemotherapy may be myelotoxic, leading to anemia,
which decreases the oxygen transport to the muscles [10]. In
addition chemotherapy, particularly anthracyclines and irradia-
tion of the mediastinum may result in myocardial damage and
can therefore lead to a decrease in cardiac output or damage
to the lungs [10]. Immunosuppressive agents may cause a
marked loss of muscle mass [10]. Furthermore, anorexia and
nausea caused by chemotherapy result in a reduced protein
and calorie intake [10]. All these side effects may impair the
physical performance in cancer patients [3,4]. Moreover,
inactivity related to disease and/or treatment may cause
deconditioning [5]. One study showed that in cancer patients,
a maximum oxygen uptake (VO2max) of 14 ml/kg/min is not
uncommon, which is even below the level of 15 ml/kg/min,
which is the limit for activities for daily life [11,12].
In the past, patients were advised to rest and avoid physical
effort. However, it is now well established that a decrease in
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physical activity results in severe deconditioning [10]. Physical
exercise may have beneficial effects on reducing cancer-related
fatigue, both during and following the administration of
adjuvant therapies [7,13–16]. Research has shown that physical
activity after chemotherapy increases muscle strength, quality
of life and return to work. Furthermore, it decreases cancer-
related fatigue. Physical activity is generally well tolerated and
only a few adverse events, such as shoulder tendonitis, knee
injury and syncope, during training occur [7,15,16].
The American College of Sports Medicine (ACSM) identifies
types of exercise in their document ‘General Principles of
Exercise Prescription’. The types of exercise can be, among
others, divided into aerobic exercise training and muscle
exercise training. Aerobic exercise training improves body
composition and cardiorespiratory fitness, while muscle
exercise training improves muscle strength and muscle
endurance. Any activity that uses large muscle groups can
be maintained continuously and is rhythmical in nature can be
regarded as an aerobic exercise. Muscle strengthening
exercises enable muscles to do more work than they are
accustomed. The aerobic intensity (training dose) can be
expressed as a percentage of a person’s VO2max/aerobic
capacity or as a percentage of a person’s maximum heart rate
(HRmax), which could be measured by exercise tests. Moderate
exercise is performed at 65–75% of HRmax and vigorous
exercise is performed at 75–95% of HRmax. To approximate the
appropriate limb-specific weight loads for resistance exercise
(training dose), one can determine the one-repetition max-
imum (i.e. 1-RM) – the greatest resistance/weight that can be
moved through the full range of motion for a single repetition
in a controlled manner and then lift a defined percentage of
that amount during each set of the exercise (i.e. % 1-RM) [17].
The ACSM advises a combination of aerobic training and
progressive resistance training on moderate intensity for
people training after chemotherapy. In concordance with the
most recent literature the ACSM [18] also advises training
during treatment with chemotherapy. Unfortunately, there is
no guideline concerning which type of training and which
training dose are effective.
Objectives
There is a lot of evidence that training after chemotherapy is
very effective. There are guidelines providing training prescrip-
tion after chemotherapy. Up to now it is not known what
training program is the most effective in training patients
during chemotherapy. The purpose of this paper is to gain
insight in the different training modalities during chemother-
apy, focusing on the most effective way to improve endurance
capacity and muscle strength, using objectively measurable
outcomes in order to compose a training program which trains
cancer patients in the most effective way.
Materials and methods
Eligibility criteria
Inclusion criteria
(1) Randomized controlled trials.
(2) Studies involving adult patients (418 years), diagnosed
for malignancy and receiving chemotherapy.
(3) Articles prescribing a physical exercise program, regard-
less of which type of exercise was prescribed.
(4) Studies prescribing training during chemotherapy.
(5) Studies using objective measurements of muscle strength
or endurance capacity.
Exclusion criteria
(1) Reviews, case reports, study protocols and animal studies.
(2) Studies with patients treated with palliative intention, for
this is a very heterogeneous group of patients.
(3) Studies involving children.
(4) Studies prescribing training after chemotherapy.
(5) Studies measuring muscle strength or endurance capa-
city using questionnaires.
Database search
A database search of PubMed up to and including January
2015 was performed, limited to studies in English, German and
Dutch languages. Also the reference lists of relevant papers
were searched for additional articles. The search was
performed using the following terms: neoplasms OR neo-
plasm* OR cancer OR tumor OR tumors OR tumor* AND
chemotherapy OR chemotherap* AND exercise therapy OR
exercise.
The effects of the studies were graded according to the best
evidence of Steultjens et al. [19]. The quality of the evidence
was categorized into strong evidence, moderate evidence,
limited evidence, indicative findings or no evidence [19,20].
Methodological quality
Study quality was assessed based on ‘‘The Dutch Cochrane
form for the assessment of randomized controlled trials’’ [21].
However, two of the three criteria for blinding procedures
could not be rated, because in physical activity interventions it
is impossible to blind patients and care providers to the
treatment assignment. Therefore the following seven criteria
were applied and were rated as follows: yes (+), no (-), partially
(+/-) or unclear (?).
(1) Were subjects randomly allocated?
(2) Was allocation concealed?
(3) Was there blinding of outcome assessors?
(4) Were the groups similar at baseline?
(5) Is loss to follow-up less than 80%?
(6) Is an intention-to-treat analysis done?
(7) Were the two groups treated equally, except for the
intervention?
Results
Study selection
The search resulted into 809 papers. The papers were screened
for title and abstract by OH and CvM. In case of disagreement a
third author was consulted. Twelve articles were selected for
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eligibility testing. Hand searching of the reference list of
relevant reviews resulted in three additional articles. One article
was excluded because it used the same data as another study,
and focused mainly on hemoglobin changes during training
[22]. In total 14 articles were included.
Quality assessment
Ratings of different quality criteria varied considerably (Table I).
The median score for quality was 4.25, ranging from 1 to 7.
Only one study met all the criteria. Only five studies (38%) had
adequate allocation concealment. Blinding of the outcome
assessors was fulfilled only in three studies. In most studies
both study groups did not differ on baseline characteristic.
Only a few studies took the drop-outs into account in their
analyses and did an intention-to-treat analysis. In five studies
the quality was very low, only scoring 1–3.5 of a maximum of
seven criteria of the Cochrane Library Assessment forms. In
these studies, besides the criteria mentioned in Table I, the
outcome assessment was of low quality, the reasons for loss-
to-follow-up were not mentioned [23], people trained in the
control groups as well [24,25], or the training program was of
very long duration [24].
Subjects
Eight (46%) studies involved a total number of 595 breast
cancer patients. Six studies (46%) involved patients with
hematologic malignancies, resulting in a total number of 317
patients. Four studies selected cancer patient receiving stem
cell transplantations. Three studies involved a heterogeneous
group of cancer patients (Table II).
The fitness level of the participants varied among the
different studies. In the studies by Al-Majid, Hornsby and
Campbell relatively young and fit breast cancer patients were
recruited [26–28]. While Oechsle, Dimeo and Chang recruited
relatively unfit patients, with hematological cancer types and
Eastern Cooperative Oncology Group performance scores
ranging from 0 to 3 [29–31]. Adherence among the different
articles ranged from 66% to 82%.
The duration of the programs ranged from 3 to 52 weeks,
with a median of 13.5 weeks. The frequency of the training
sessions ranged from two to seven times per week, with a
median of 5.5 sessions per week. Ten studies (71%) provided a
supervised training program, three studies (23%) provided a
home-based program and one study provided both (Table III).
In six studies (43%) a combination of resistance and aerobic
training was applied. Six studies only focused on aerobic
training. Only nine studies were accurate in describing the
intensity of the training or the number of sets and repetitions.
In the resistance exercises the intensity varied from 40% to
100% of 1-RM, and was mostly between 60% and 70% of 1-RM.
All programs focused on large muscle groups and two studies
used theraband exercises as training.
In the aerobic training stationary cycling and walking were
prescribed most frequently. Three studies (23%) provided a
walking program only [25,29,32]. The intensities varied from
50% to 100% of VO2max or HRmax. Several studies provided a
high-intensity program with intensities ranging from 60% to
100% of HRmax or VO2peak [26,33–35], and others a more
moderate program with intensities ranging from 50% to 70%
of HRmax or VO2max [24,25,27,29,30,32]. The duration of the
aerobic training was mostly between 10 and 30 minutes.
Endurance capacity
Variables of endurance capacity were assessed in 17 different
intervention groups (14 articles) and reported beneficial effects
in 10 groups (59%). Direct measurement of VO2max, which is
the gold standard for measuring endurance capacity, was
assessed in five intervention groups [25,27,31,32,34], indirect
measurement of VO2max was measured in two intervention
groups [27,28] (Table V). The studies reported significant
increases due to training, which ranged from 8% to 31%.
Endurance capacity decreased in nine of 13 control groups
(69%), which ranged from 1% to 32% (Table VI). Effect sizes
were very high in the papers of Al-Majid, and Campbell, 2, 7
and 2.3, respectively [26,28]. An effect size around 1 was
calculated in the papers of Schwartz, Hornsby and Coleman
[23,24,27] (Table IV).
Muscle strength
Muscle strength was assessed by means of a 1-RM test. Muscle
strength improved significantly in 17 of 18 intervention groups
(94%), ranging from 2% to 38%. Measures of upper body
Table I. Quality assessment of the studies.
Randomization
Allocation
concealment Blinding
Baseline
criteria Follow-up Intention-to-treat Contamination Total max¼7
Hornsby et al. + + + - + ? + 5
Coleman et al. + ? ? + - - - 2
Lin et al. - + ? + ? + +/-+ 3,5
Oechsle et al. + ? ? + + - + 4
Courneya et al. + + ? + + + + 6
Adamsen et al. + + + + + + + 7
Dimeo et al. + ? + + + + +/- 5,5
Campbell et al. + ? ? + + +/- + 4,5
Schwartz et al. + ? ? + - + - 3
Baumann et al. + ? - - - - - 1
Segal et al. + + ? + + + + 6
Chang et al. + ? - + + ? + 4
Griffith et al. + ? ? + - - - 2
Al-Majid et al. + ? ? + + + + 5
+¼ 1 point, +/-¼ 0.5 point.
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strength (chest press) and lower body strength (leg press) were
measured in nine intervention groups [24,33–35], and showed
an increase in eight groups. The increase on the leg press
ranged from 4% to 33% and the increase in chest press ranged
from 12% to 38%. Muscle strength also improved in 11 of 14
control groups (79%), but this increase was only minimal,
ranging from 1.3% to 6.5%. An effect size of 0.3–0.8 was
calculated in the papers of Courneya, Adamsen and Schwartz
[24,33,34].
Discussion
Summary of evidence
This paper gains insight into the different training modalities
during cancer treatment with chemotherapy and focuses on
the most effective way to improve physical fitness and muscle
strength. The objective was to compose a training program in
which people undergoing chemotherapy could be trained in
the most effective way. In total 14 papers could be identified
in which a training program during chemotherapy was
compared to a control group. In addition to earlier reported
improvements in cancer-related fatigue [16] these papers
provide evidence to suggest that an exercise intervention
during treatment with chemotherapy is associated with
significant improvements in muscle strength as well as
endurance capacity. Although the purpose of this study was
to find the most effective way to improve endurance capacity
and muscle strength, the papers were too heterogeneous to
draw a distinct conclusion. Also, there was a lack in a
consistent methodological approach in the dose of the
training.
Limitations
This review is based on a small number of papers (n¼ 14), their
poor methodological quality suggests that not much research
on this specific topic has been done so far. Most research has
been done on quality of life or cancer-related fatigue [7,13–16].
Furthermore, there was a large diversity in the study
populations which ranged from very fit to unfit patients.
There was also a considerable heterogeneity in tumor types,
tumor stage and outcome measures.Ta
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Table III. Overview of the training programs.
Primary author
Duration
(weeks)
Frequency
(session/week)
Supervised/
home-based
Hornsby et al., 2014 12 3 Supervised
Coleman et al., 2012 15 3–4 Home-based
Lin et al., 2013 12 2 Supervised
Oechsle et al., 2014 3 5 Supervised
Courneya et al., 2007 18 3 Supervised
Adamsen et al., 2009 6 5 Supervised
Dimeo et al., 1997 Unspecified 7 Supervised
Campbell et al., 2005 12 2 Supervised
Schwartz and Winters-Stone, 2009 52 4 Home-based
Baumann et al., 2011 2.5 7 Supervised
Segal et al., 2001 26 5 Supervised
+ home-based
Chang et al., 2008 3 5 Supervised
Griffith et al., 2009 13 5 Home-based
Al-Majid et al., 2015 9–12 5–6 Supervised
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The participation level in most papers was low. This
suggests that only motivated patients participated in the
studies. This is an important finding, it may have influenced
the results, but is also a point of concern for future training
programs, as unmotivated patients should be more encour-
aged and involved into training programs. As a result of the
heterogeneity on several topics it was not possible to provide
a meta-analysis. This was also the case in other reviews,
focusing on the specific outcomes of objectively measured
improvements in aerobic capacity and muscle strength
[36,37]. Another limitation is the fact that only PubMed was
searched, limiting the number of articles. Furthermore, we
had to exclude some studies, e.g. a randomized controlled
trial by Courneya et al. [38] in which no difference could be
made between patients during and off treatment with
chemotherapy.
Endurance capacity
Our review showed a general increase in endurance capacity. In
people receiving chemotherapy for the treatment of lympho-
mas while not training, Vermaete et al. found a decrease of
7.8% in endurance capacity (VO2max) [39]. The magnitude of
the improvement in our review, however, was inconsistent
among the different groups. The improvement ranged from 4%
to 33%. The greatest increase was seen in the study by
Campbell et al. [26], which showed a 31% improvement on the
12-minute walking test after a follow-up of 12 weeks.
Unfortunately, the sample size in this study was very small
and the methodological quality was moderate. The calculated
effect sizes were the highest in the papers by Campbell and Al-
Majid, suggesting that the most effective training intensity
ranges from 60% to 80% of maximum heart rate. The subjects
in these papers were relatively fit breast cancer patients. In the
paper by Courneya et al., lymphoma patients were provided
with aerobic exercise training for 12 weeks. At post-interven-
tion, the aerobic exercise training group was superior to the
usual care group on all indicators of physical fitness, including
VO2max [38]. This is comparable to the results of this review.
Muscle strength
Chemotherapy normally causes a severe decrease in muscle
strength, especially in striated muscles [40]. Vermaete et al.
showed a decrease of 5.6–14.6% in muscle strength in people
not training and receiving chemotherapy for lymphoma [39]. In
our review the muscle strength improved in the intervention
groups as well as in the control groups, although the increase
in the control groups was only minimal. A reason for the
increase could be the high level of contamination. Many
people in the control groups did a lot of training by
themselves. This may have influenced the results. The
calculated effect sizes were the highest in the papers of
Courneya, Adamsen and Schwartz, the patients in these papers
trained in 60–100% of 1-RM, in 2–3 sets of 5–12 repetitions.
This suggests that the most effective training intensity is in that
range. This is in concordance with De Backer et al., in which
patients were trained after receiving chemotherapy. The
patients trained at an intensity level of 65–80% of 1-RM in
two sets of 10 repetitions, with an effect size of 1.3–2.7 [7]. This
paper also showed long-term effects of a maintained muscle
strength and quicker return to work [8].
Recent research suggests that cancer survivors experience
participation in exercise-based rehabilitation as a means to
fulfil their mental, social and physical well being independent
of disease status [41]. Other papers suggest associations
between lifetime and recent pre-diagnosis recreational physical
activity and risk of all-cause death [42]. We continually need to
raise awareness among health professionals to continue to
suggest modifications to impact on fatigue and physical
performance at all stages of cancer treatment and into
survivorship and late effects [43].
It is important to know which training intensity and duration
is the most effective in training cancer patients in order to
provide a training program suitable for every cancer patient.
Training should be based on good research and implemented
Table VI. Physical outcome measures of muscle strength in the intervention
groups and control groups.
Outcome
measure (1-RM)
Number of
intervention
groups
assessed Increase Decrease No-effect
Best evidence
synthesis
Intervention groups
Leg press 6 6 0 0 Moderate
Chest press 3 2 1 0 Strong
Hand grip strength 2 2 0 0 Indicative findings
Pull down 1 1 0 0 Low
Bridging 1 1 0 0 Indicative findings
Sit-ups 1 1 0 0 Indicative findings
Seated row 2 2 0 0 Indicative findings
Overhead press 2 2 0 0 Indicative findings
TOTAL 18 17 1 0
Control groups
Leg press 4 4 0 0 Moderate
Chest press 3 2 1 0 Strong
Hand grip strength 2 2 0 0 Indicative findings
Pull down 1 1 0 0 Low
Bridging 1 1 0 0 Indicative findings
Sit-ups 1 1 0 0 Indicative findings
Seated row 1 0 1 0 Indicative findings
Overhead press 1 0 1 0 Indicative findings
TOTAL 14 11 3 0
Table V. Physical outcome measures of endurance capacity in the intervention
groups and control groups.
Outcome measure
Number of
intervention
groups
assessed Increase Decrease No-effect
Best
evidence
synthesis
Intervention groups
VO2max (ml/kg/min) 7 4 3 1 Moderate evidence
VO2max (l/min) 1 1 0 0 Low evidence
12MWT 4 4 0 0 Low evidence
6MWT 2 1 1 0 No evidence
Walking speed (km/h) 1 0 1 0 Limited evidence
Watt 1 0 0 1 No evidence
TOTAL 17 10 5 2
Control groups
VO2max (ml/kg/min) 6 0 4 2 Moderate evidence
VO2max (l/min) 1 1 0 0 Low evidence
12MWT 3 0 3 0 Low evidence
6MWT 2 1 0 1 No evidence
Walking speed (km/h) 1 0 1 0 Limited evidence
Watt 1 0 1 0 No evidence
TOTAL 14 2 9 3
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into international guidelines. Furthermore, it should be
implemented into daily practice.
Conclusion
This literature review focuses specifically on the objectively
assessed outcome measures muscle strength and endurance
capacity in training programs during chemotherapy. It shows
that training during chemotherapy is an effective way to
improve muscle strength and endurance capacity in cancer
patients. The overall positive results of training may warrant a
more active approach to incorporate training in standard care.
Given the limited availability of studies and the lack of
standardization it is currently still unclear what training
modalities are the best way to improve muscle strength and
physical fitness. Future research should specifically focus on
finding the most effective exercise intensity with the aim to
gain insight into the most effective way to improve both
muscle strength and endurance capacity in different patient
groups.
Suggestions for future research
Future research should use valid and reliable physical outcome
measures, such as VO2peak and upper- and lower body
strength measures (1-RM). Furthermore, it is important to blind
the outcome assessors. Also, a detailed prescription of the
exercise intervention in terms of duration, intensity and
frequency should be provided.
Although it is important to compare an intervention group
to a control group, the high level of contamination suggests
that this is difficult in daily practice. Patients participating in a
study who are allocated to a control group tend to start
training by themselves. A fair approach is to use a different
method of research, such as clinical comparative research
which is more practice based and combines implementation of
effective intervention with research aiming to optimize these
interventions [44].
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